EU concerned over BBC ban, RTHK’s response

2021-02-12 HKT 21:08" title="The European Union said it saw RTHK's decision as a "further erosion" of the SAR's autonomy. File image: Shutterstock"> The European Union said it saw RTHK's decision as a "further erosion" of the SAR's autonomy. File image: Shutterstock The European Union has issued a statement criticising a...

APOLLOMICS(冠科美博)在中國和南非引進一款靶向主動免疫檢查點控制劑重組疫苗

FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Feb 12, 2021 - (亞太商訊) - Apollomics, Inc. (冠科美博),一家致力於發現和開發腫瘤靶向和免疫新藥及其組合療法的創新生物製藥公司,今天宣佈一份獨家許可協定,根據協議,冠科美博獲得TYG100在中國(中國大陸、香港、澳門和台灣)和南非的開發和商業化權利。TYG100是一種抗原特異性免疫檢查點主動控制劑(ACCI)重組疫苗,通過S-TIR(TM)技術平台,複合了免疫原G17(胃泌素)末端氨基酸序列。S-TIR(TM)技術開創了一種新穎的作用機制,使TYG100可以識別腫瘤細胞。TYG100由總部位於英國的TYG oncology Ltd.開發,並且獲得了Cancer Research UK的資助。TYG oncology最初授權Nuance Biotech共同開發TYG100,現在該許可已轉讓給冠科美博做進一步合作開發。 冠科美博首席執行官余國良博士說:「TYG100可以實現快速且可控的自然免疫反應,代表了主動免疫檢查控制點療法的新時代。另外,這項技術還可以使TYG100在腫瘤部位靶向中和G17抗體。 我們非常看好這項技術,儘管該產品還處於早期階段,在完成臨床前研究後,有望在消化道腫瘤上開展臨床試驗。」根據協議,冠科美博將負責TYG100在中國和南非的臨床開發和商業化,並承擔在這些地區開發、審批和商業化相關的所有費用。Nuance Biotech已收到一筆首付款,並且有資格獲得潛在的開發里程碑付款。TYG oncology將有資格獲得銷售分成形式的授權使用費。Nuance Biotech首席執行官Jian Ni補充到:「ACCI打開了腫瘤新療法的大門,是超越免疫檢查點抑製劑的新一代免疫療法。 臨床前數據顯示TYG100可以激發明顯的免疫反應,在靈長類動物上耐受性良好,有潛力實現高水平的免疫反應。」TYG Oncology首席執行官Fred Jacobs總結說:「我們感謝Nuance在將TYG100轉給冠科美博進行下一階段開發的合作中提供的説明。很高興能和這樣強大的夥伴合作,將TYG100推向臨床並有機會救治患者。」關於TYG100TYG100是一款針對胃泌素免疫原的主動免疫檢查點控制劑(ACCI)重組疫苗。在臨床前研究中,TYG100可以誘導針對胃泌素的中和抗體,胃泌素是胰腺癌和其他消化道腫瘤的一個主要生長因子。相關更多信息,請訪問 https://www.tyg-oncology.com。 關於Apollomics, Inc.Apollomics, Inc. (冠科美博)是一家創新型生物製藥公司,致力於研發腫瘤靶向和免疫單葯及其組合療法,在美國加州福斯特市和中國杭州市均有運營實體。公司產品管線有多個處於不同開發階段的項目,包括為恢復機體免疫系統識別能力和殺死癌細胞的新型人源化單克隆抗體和為針對失控的生長信號通路的靶向療法。欲了解更多信息,請訪問 www.apollomicsinc.com 。 冠科美博聯繫方式:投資人聯繫人:Wilson W. Cheung首席財務官電話:+1-650-209-4436電郵:wcheung@apollomicsinc.com公司聯繫人:張立平電話:+86-571-83521933電郵:liping.zhang@apollomicsinc.com中國媒體聯繫:博達浩華國際財經傳訊集團馮嘉莉總經理電話:+852-3150 6763電郵: kelly.fung@pordahavas.com馮靜儀助理副總裁電話:+852-3150 6773電郵: phoenix.fung@pordahavas.com Copyright 2021 亞太商訊. All rights...

Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa

FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Feb 12, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong,...

Woman arrested over ‘protest slogan vandalism’

2021-02-11 HKT 18:08" title="The police displayed on their Facebook page some of the items they had seized."> The police displayed on their Facebook page some of the items they had seized. Police have arrested a 57-year-old woman suspected of vandalising a number of items in Hung Hom by writing protest...

Health officials find little use for govt Covid app

Health officials find little use for govt Covid app Health officials say they have so far used the government’s LeaveHomeSafe contact-tracing app fewer than 20 times since it was launched in November last year, and it hasn't led to the discovery of any Covid-19 infections. The government says from February...

Elastomers develop stronger bonds of attachment

Tsukuba, Japan, Feb 12, 2021 - (ACN Newswire) - Elastomers are the soft, elastic materials, like gels and rubbers, that are found in automobile and airplane parts, in sports equipment, and are used to protect precision machinery and buildings against vibrations. Scientists now want to make them thinner and tougher,...